At the cusp of NDA filing for lead antibiotic, AstraZeneca spinout goes private at a fraction of IPO price

Seven years after a group of AstraZeneca vets salvaged a suite of programs from the then newly-shuttered antibiotics division and spun them into a new biotech named Entasis, those still-experimental antibiotics are getting a new home.